Dr. Quaggin’s research focuses on fundamental processes needed to establishand maintain theintegrity of the specialized vascular beds in the kidney and eye. To understand and identify new therapeutic targets, she’s worked to develop genetic mouse models that allow cell and time-specificmanipulation of functional genes. Translation of her group’s findings regarding the vasculature reveals pathogenic mechanismsand new therapeutic targets for a number of diseases, including diabetic kidney and eye disease, nephrotic syndrome, and glaucoma.
Dr. Quaggin was elected to the American Society for Clinical Investigation in 2006, the Association of American Physicians in 2013, the National Academy of Medicine in 2019, the National Academy of Inventors in 2021, the American Academy of Arts & Sciences (2023), and served as President of the American Society of Nephrology (2021,2022) and is serving as council member of the Association of American Physicians. She was co-recipient of the Lefoulon-Delalande Grand Prix in Cardiovascular Science (2023).